Sacituzumab Govitecan In TNBC
Public ClinicalTrials.gov record NCT04230109. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)
Study identification
- NCT ID
- NCT04230109
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Massachusetts General Hospital
- Other
- Enrollment
- 239 participants
Conditions and interventions
Conditions
Interventions
- Sacituzumab Govitecan Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2020
- Primary completion
- Sep 30, 2028
- Completion
- Sep 30, 2029
- Last update posted
- Jul 16, 2026
2020 – 2029
United States locations
- U.S. sites
- 5
- U.S. states
- 1
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02115 | Active, not recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02115 | Recruiting |
| Massachusetts General Hospital - North Shore Cancer Center | Danvers | Massachusetts | 01923 | Recruiting |
| Massachusetts General Hospital at Newton-Wellesley Hospital | Newton | Massachusetts | 02462 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04230109, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04230109 live on ClinicalTrials.gov.